LOW DOSE SURAMIN AS A CHEMOSENSITIZER OF BLADDER CANCER TO MITOMYCIN C

Abstract

Low dose suramin enhanced the in vitro and in vivo activity of subtherapeutic and therapeutic MMC without enhancing host toxicity, thus, providing proof of concept for evaluating low dose suramin as a chemosensitizer with MMC in bladder cancer.